Cargando…
HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B
The aim of this study was to assess HBV DNA suppression after 24 weeks of treatment with entecavir in previously treated children with CHB. Thirty children aged 5–17 years (25 males and 5 females) with CHB were treated with entecavir 0.5 or 1 mg daily. Twenty-two children were HBeAg-positive, eight...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303069/ https://www.ncbi.nlm.nih.gov/pubmed/21796345 http://dx.doi.org/10.1007/s10096-011-1349-0 |
_version_ | 1782226716859564032 |
---|---|
author | Pawłowska, M. Halota, W. Smukalska, E. Woźniakowska-Gęsicka, T. Kupś, J. |
author_facet | Pawłowska, M. Halota, W. Smukalska, E. Woźniakowska-Gęsicka, T. Kupś, J. |
author_sort | Pawłowska, M. |
collection | PubMed |
description | The aim of this study was to assess HBV DNA suppression after 24 weeks of treatment with entecavir in previously treated children with CHB. Thirty children aged 5–17 years (25 males and 5 females) with CHB were treated with entecavir 0.5 or 1 mg daily. Twenty-two children were HBeAg-positive, eight were HBeAg-negative, and in eight HBV polymerase mutations were detected. After 24 weeks of treatment, mean and median HBV DNA levels and ALT activity were lower versus baseline, overall and in both subgroups. The overall median HBV DNA level decreased from 1.2 x 10(7) IU/mL to 3.3 x 10(2) IU/mL (p < 0.000004), in HBeAg-positive from 7.8x10(7) IU/mL to 6.3x10(3) IU/mL (p < 0.00004), and in HBeAg-negative from 2.5x10(4) IU/mL to 5.01x10(1) IU/mL (p < 0.03). The serum HBV DNA disappearance was observed in 7/8 (88%) HBeAg-negative and in 5/22 (23%) HBeAg-positive patients. The overall mean ALT activity decreased from 164+ 290 U/L to 34.1+ 18.9 U/L (p < 0.000007), in HBeAg-positive from 214+326 U/L to 38.59+19.2 U/L (p < 0.000074), and in HBeAg-negative from 27+14 U/L to 20+8 U/L (p < 0.03). Twenty-four weeks of treatment with entecavir results in suppression of HBV DNA in a substantial proportion of children previously treated ineffectively with CHB. |
format | Online Article Text |
id | pubmed-3303069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-33030692012-03-22 HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B Pawłowska, M. Halota, W. Smukalska, E. Woźniakowska-Gęsicka, T. Kupś, J. Eur J Clin Microbiol Infect Dis Article The aim of this study was to assess HBV DNA suppression after 24 weeks of treatment with entecavir in previously treated children with CHB. Thirty children aged 5–17 years (25 males and 5 females) with CHB were treated with entecavir 0.5 or 1 mg daily. Twenty-two children were HBeAg-positive, eight were HBeAg-negative, and in eight HBV polymerase mutations were detected. After 24 weeks of treatment, mean and median HBV DNA levels and ALT activity were lower versus baseline, overall and in both subgroups. The overall median HBV DNA level decreased from 1.2 x 10(7) IU/mL to 3.3 x 10(2) IU/mL (p < 0.000004), in HBeAg-positive from 7.8x10(7) IU/mL to 6.3x10(3) IU/mL (p < 0.00004), and in HBeAg-negative from 2.5x10(4) IU/mL to 5.01x10(1) IU/mL (p < 0.03). The serum HBV DNA disappearance was observed in 7/8 (88%) HBeAg-negative and in 5/22 (23%) HBeAg-positive patients. The overall mean ALT activity decreased from 164+ 290 U/L to 34.1+ 18.9 U/L (p < 0.000007), in HBeAg-positive from 214+326 U/L to 38.59+19.2 U/L (p < 0.000074), and in HBeAg-negative from 27+14 U/L to 20+8 U/L (p < 0.03). Twenty-four weeks of treatment with entecavir results in suppression of HBV DNA in a substantial proportion of children previously treated ineffectively with CHB. Springer-Verlag 2011-07-29 2012 /pmc/articles/PMC3303069/ /pubmed/21796345 http://dx.doi.org/10.1007/s10096-011-1349-0 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Pawłowska, M. Halota, W. Smukalska, E. Woźniakowska-Gęsicka, T. Kupś, J. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B |
title | HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B |
title_full | HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B |
title_fullStr | HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B |
title_full_unstemmed | HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B |
title_short | HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B |
title_sort | hbv dna suppression during entecavir treatment in previously treated children with chronic hepatitis b |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303069/ https://www.ncbi.nlm.nih.gov/pubmed/21796345 http://dx.doi.org/10.1007/s10096-011-1349-0 |
work_keys_str_mv | AT pawłowskam hbvdnasuppressionduringentecavirtreatmentinpreviouslytreatedchildrenwithchronichepatitisb AT halotaw hbvdnasuppressionduringentecavirtreatmentinpreviouslytreatedchildrenwithchronichepatitisb AT smukalskae hbvdnasuppressionduringentecavirtreatmentinpreviouslytreatedchildrenwithchronichepatitisb AT wozniakowskagesickat hbvdnasuppressionduringentecavirtreatmentinpreviouslytreatedchildrenwithchronichepatitisb AT kupsj hbvdnasuppressionduringentecavirtreatmentinpreviouslytreatedchildrenwithchronichepatitisb |